Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Nashville, Tennessee 37232


Purpose:

This study will test an investigational drug, theophylline, in children with pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the Vanderbilt Clinical Research Center.


Study summary:

Study measures will be done at baseline and during a 24h infusion of IV theophylline. Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity. Measures include laboratory values, response to PTH infusion and resting energy expenditure.


Criteria:

Inclusion Criteria: 1. Age 10 to 21 years old 2. English proficiency 3. Clinical and genetic diagnosis of PHP1a Exclusion Criteria: 1. Use of a PDE inhibitor in the past 30 days 2. History of a seizure disorder unrelated to hypocalcemia 3. History of a cardiac arrhythmia (not including bradycardia) 4. History of hepatic insufficiency 5. AST or ALT >2x upper limit of normal 6. Total bilirubin >1.5 x upper limit of normal (unless patient has a diagnosis of Gilbert's syndrome and no other causes leading to hyperbilirubinemia are identified) 7. Congestive heart failure 8. Cigarette use in the past 30 days 9. Alcohol use within the past 24 hours 10. Current pregnancy 11. Untreated hypothyroidism (defined as free T4 level < 0.6 ng/dL or TSH >10 mcU/mL) 12. Active peptic ulcer disease 13. Fever >101 degrees in the past 24 hours 14. Current use of medications known to effect theophylline levels (listed below) 15. Severe sleep apnea requiring BiPAP Drugs with clinically significant drug interactions with theophylline: - Allopurinol - Cimetidine - Ciprofloxacin - Clarithromycin - Enoxacin - Ephedrine - Erythromycin - Estrogen - Flurazepam - Fluvoxamine - Lithium - Lorazepam - Methotrexate - Midazolam - Pentoxifylline - Propranolol - Rifampin - Sulfinpyrazone - Tacrine - Thiabendazole - Ticlopidine - Troleandomycin - Verapamil


NCT ID:

NCT02463409


Primary Contact:

Principal Investigator
Ashley H Shoemaker, MD, MSCI
Vanderbilt University


Backup Contact:

N/A


Location Contact:

Nashville, Tennessee 37232
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.